New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p...

The consensus price target hints at a 45.9% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

LDOS, AMZN, HALO & BMRN's impressive interest coverage ratios highlight that these companies can withstand financial hardships.

For a second straight year, investors have been given every reason to smile. As of this writing, with one trading day left in 2024, the iconic Dow Jones Industrial Average, benchmark S&P 500, and grow...

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either BioMarin Pharmaceutical (BMRN) or Techne (TECH). But which of these two stocks presents inves...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors need to pay close attention to BioMarin Pharmaceutical (BMRN) stock based on the movements in the options market lately.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock?

BioMarin Pharmaceutical NASDAQ: BMRN has been a rough investment for a long time. Over the past 10 years, shares have provided a total return of -28%.

Biomarin has a near $3bn per annum rare disease drug franchise, and is profitable. Arguably the business is undervalued by the market. The company faces threats to key drugs in the indications of acon...

BioMarin (BMRN) is well positioned to outperform the market, as it exhibits above-average growth in financials.

BioMarin (BMRN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of BioMarin Pharmaceutical (BMRN) and Incyte (INCY). But which of these two companies is th...

BMRN reports better-than-expected third-quarter results, beating both earnings and sales estimates. Management raises 2024 guidance.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Traci McCarty - Head of Investor Relations Alexander Hardy - President and...